This finding is in line with previous studies which reported that EGFR mutation was significantly correlated with overexpression of HHLA2. This indicates that HHLA2 is a potentially novel target for lung cancer immunotherapy, especially in patients with EGFR expression. The gene discussed is HHLA2; the disease is lung carcinoma.